From Iran to China: An Emerging Trans-Central Asian Corridor 
New documents show how a retail chain’s sales practices helped put guns on US streets 
Singapore a battleground of commodities fraud lawsuits The World Health Organization announced on Friday that it had given prequalification approval to a malaria treatment for newborns and infants for the first time.
Artemether-lumefantrine is the first antimalarial formulation designed specifically for the youngest victims of the mosquito-borne disease.
“The prequalification designation indicates that the medicine meets international standards of quality, safety and efficacy,” the WHO said in a statement.
Advertisement
Up to now, infants have been treated with formulations intended for older children – carrying a greater risk of dosage errors, side effects and toxicity.
“For centuries, malaria has stolen children from their parents, and health, wealth and hope from communities,” WHO chief Tedros Adhanom Ghebreyesus said.
“But today, the story is changing. New vaccines, diagnostic tests, next-generation mosquito nets and effective medicines, including those adapted for the youngest, are helping to turn the tide.
Advertisement
Don't Miss:
-
John Lee promises ‘high-quality’ experience for Apec finance meeting guests
-
John Lee urges public to tune in to Legco debate on city’s 5-year plan, policy address
-
Hong Kong prepares reforms, accountability measures ahead of Tai Po fire report
-
Turkmenistan grows its arsenal of Chinese air defences as Russia’s role shrinks
-
India sizes up US F-35 stealth jets in landmark first on home turf